IKONISYS EO 2
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more
Market Cap & Net Worth: IKONISYS EO 2 (9W8)
IKONISYS EO 2 (F:9W8) has a market capitalization of $22.57 Million (€21.99 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #28415 globally and #3112 in its home market, demonstrating a -2.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IKONISYS EO 2's stock price €1.39 by its total outstanding shares 15819899 (15.82 Million).
IKONISYS EO 2 Market Cap History: 2021 to 2026
IKONISYS EO 2's market capitalization history from 2021 to 2026. Data shows change from $46.61 Million to $22.57 Million (-19.73% CAGR).
IKONISYS EO 2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IKONISYS EO 2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9W8 by Market Capitalization
Companies near IKONISYS EO 2 in the global market cap rankings as of March 19, 2026.
Key companies related to IKONISYS EO 2 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
IKONISYS EO 2 Historical Marketcap From 2021 to 2026
Between 2021 and today, IKONISYS EO 2's market cap moved from $46.61 Million to $ 22.57 Million, with a yearly change of -19.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €22.57 Million | -6.40% |
| 2025 | €24.11 Million | +11.65% |
| 2024 | €21.60 Million | -18.40% |
| 2023 | €26.47 Million | +26.36% |
| 2022 | €20.95 Million | -55.05% |
| 2021 | €46.61 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IKONISYS EO 2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.57 Million USD |
| MoneyControl | $22.57 Million USD |
| MarketWatch | $22.57 Million USD |
| marketcap.company | $22.57 Million USD |
| Reuters | $22.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.